Literature DB >> 3881332

Insulin action in cirrhosis.

R Taylor, R J Heine, J Collins, O F James, K G Alberti.   

Abstract

In vivo insulin sensitivity and adipocyte insulin binding and action were assessed in 16 patients with histologically proven hepatic cirrhosis and 11 age-, weight- and sex-matched normal control subjects. The cirrhotic group displayed impaired oral glucose tolerance, despite an exaggerated serum immunoreactive insulin response, and in vivo insulin resistance as assessed both by the euglycemic hyperinsulinemic clamp and the glucose-insulin infusion techniques. Adipocytes of the cirrhotic patients bound significantly less insulin than those of the control subjects (2.21 +/- 0.12% vs. 2.64 +/- 0.13%; p less than 0.05). Although the adipocytes from the cirrhotic patients were less sensitive to insulin stimulation in vitro (half-maximal stimulation at 60.0 +/- 8.0 vs. 21.8 +/- 3.3 pM; p less than 0.001), they exhibited higher maximum rates of lipogenesis. Comparison of the responses of the alcoholic, primary biliary cirrhosis and cryptogenic subgroups suggested pronounced differences in the maximum rates of lipogenesis. There were significant negative correlations between specific binding to adipocytes and both fasting serum immunoreactive insulin and in vivo insulin resistance as assessed by glucose-insulin infusion. Monocyte insulin binding was normal in the cirrhotic group and did not correlate with in vivo insulin resistance. It is concluded that both binding and postbinding defects in insulin target organ cells contribute to the marked in vivo insulin resistance of hepatic cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881332     DOI: 10.1002/hep.1840050115

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

Review 1.  Insulin receptors and the clinician.

Authors:  R Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

2.  Effects of collateral vessel occlusion on oral glucose tolerance test in liver cirrhosis.

Authors:  N Tanabe; M Ishii; Y Sato; T Akahane; N Kobayashi; H Gama; T Iwasaki; T Toyota
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

3.  Insulin sensitivity in experimental cirrhosis.

Authors:  S A Chowdhury; R Taylor
Journal:  Mol Cell Biochem       Date:  1989-08-15       Impact factor: 3.396

Review 4.  Adequacy and support of physiological functions in the acutely ill cirrhotic patient.

Authors:  I Giovannini; G Boldrini; C Chiarla; M Castagneto; G Sganga; G Tramutola; F Caracciolo; G Castiglioni
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

5.  Insulin binding to erythrocytes in hyperinsulinemic patients with precirrhotic hemochromatosis and cirrhosis.

Authors:  A S Petrides; W Passlack; H Reinauer; W Stremmel; G Strohmeyer
Journal:  Klin Wochenschr       Date:  1987-09-15

6.  Resistance to insulin suppression of plasma free fatty acids in liver cirrhosis.

Authors:  M Merli; F Leonetti; O Riggio; A Giaccari; A Romiti; P Sbraccia; G Tamburrano
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

7.  Mechanisms of hyperinsulinaemia in Child's disease grade B liver cirrhosis investigated in free living conditions.

Authors:  A V Greco; G Mingrone; A Mari; E Capristo; M Manco; G Gasbarrini
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

8.  In vivo insulin action in hepatocellular and cholestatic liver cirrhosis.

Authors:  N Barzilai; P Cohen; E Karnieli; R Enat; O Epstein; J Owen; N McIntyre
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

9.  Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis.

Authors:  G Marchesini; G P Bianchi; G Forlani; A G Rusticali; D Patrono; M Capelli; M Zoli; P Vannini; E Pisi
Journal:  Dig Dis Sci       Date:  1987-10       Impact factor: 3.199

10.  Metabolic handling of orally administered glucose in cirrhosis.

Authors:  Y T Kruszynska; A Meyer-Alber; F Darakhshan; P D Home; N McIntyre
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.